Isoprenoid pathway dysfunction in chronic fatigue syndrome.
Kurup, Ravi Kumar, Kurup, Parameswara Achutha · Acta neuropsychiatrica · 2003 · DOI
Quick Summary
This study looked at a set of chemical processes in the body called the isoprenoid pathway in 15 people with ME/CFS. Researchers found that several key molecules and minerals were out of balance in ME/CFS patients compared to expected levels, including low magnesium, low energy-producing compounds in cells, and imbalanced brain chemicals. These patterns were associated with increased oxidative stress (cellular damage from unstable molecules) and problems with how the immune system presents viral antigens.
Why It Matters
This mechanistic study proposes specific biochemical abnormalities in ME/CFS affecting energy metabolism, neurotransmitter balance, and immune function—pathways that could explain cardinal symptoms like fatigue and cognitive dysfunction. If validated, these biomarkers could aid in objective diagnosis and guide targeted therapeutic interventions.
Observed Findings
Decreased RBC membrane Na⁺-K⁺-ATPase activity and serum magnesium levels in ME/CFS patients
Increased serum digoxin levels and elevated HMG-CoA reductase activity
Altered neurotransmitter metabolism with increased tryptophan catabolites (quinolinic acid, nicotinic metabolites) and decreased tyrosine catabolites (dopamine, norepinephrine)
Reduced ubiquinone, reduced glutathione, and antioxidant enzyme activity with increased lipid peroxidation and nitric oxide
Elevated dolichol, glycoconjugate residues, and lysosomal enzyme markers
Inferred Conclusions
ME/CFS involves dysfunction of the isoprenoid pathway with impaired energy production and antioxidant defense at the mitochondrial level
Altered neurotransmitter catabolism may contribute to neurological symptoms through increased NMDA receptor excitotoxicity and impaired serotonin metabolism
Abnormal glycoconjugate metabolism and elevated dolichol may disrupt viral antigen presentation, affecting immune regulation
ME/CFS predominantly occurs in individuals with right hemispheric dominance, suggesting a neurobiological constitutional factor
Remaining Questions
Do the observed biochemical abnormalities precede ME/CFS onset, or do they develop as a consequence of chronic illness and immobility?
What This Study Does Not Prove
This study does not establish causation or directionality; biochemical abnormalities could be consequences rather than drivers of ME/CFS. The very small sample size, lack of matched controls, and absence of statistical analysis means findings cannot be considered generalizable or statistically significant. The proposed hemispheric dominance correlation is speculative and requires independent replication.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
What is the mechanistic link between right hemispheric dominance and these specific isoprenoid and metabolic pathway dysfunctions?
Could pharmacological intervention targeting HMG-CoA reductase, digoxin signaling, or antioxidant repletion improve ME/CFS symptoms, and in which patient subgroups?
How do these biochemical findings correlate with post-exertional malaise and physical exertion tolerance in ME/CFS?